NASDAQ:PRAX

Praxis Precision Medicines Stock Earnings Reports

etoro logo Buy PRAX
*Your capital is at risk
$303.39
+21.08 (+7.47%)
At Close: Jun 22, 2026

Praxis Precision Medicines Earnings Calls

Mar 31, 2026
-$3.20 (10.61%)
Release date May 07, 2026
EPS estimate -$3.58
EPS actual -$3.20
EPS Surprise 10.61%
Revenue estimate 100K
Revenue actual -
Dec 31, 2025
-$3.50 (-11.97%)
Release date Feb 19, 2026
EPS estimate -$3.13
EPS actual -$3.50
EPS Surprise -11.97%
Revenue estimate 66.667K
Revenue actual -
Sep 30, 2025
-$3.36 (2.61%)
Release date Nov 05, 2025
EPS estimate -$3.45
EPS actual -$3.36
EPS Surprise 2.61%
Revenue estimate 256.09K
Revenue actual -
Jun 30, 2025
-$3.31 (2.65%)
Release date Aug 04, 2025
EPS estimate -$3.40
EPS actual -$3.31
EPS Surprise 2.65%
Revenue estimate 59.44K
Revenue actual -

Last 4 Quarters for Praxis Precision Medicines

Below you can see how PRAX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Jun 30, 2025 Beat
Release date Aug 04, 2025
Price on release $51.09
EPS estimate -$3.40
EPS actual -$3.31
EPS surprise 2.65%
Date Price
Jul 29, 2025 $55.96
Jul 30, 2025 $56.59
Jul 31, 2025 $54.22
Aug 01, 2025 $54.09
Aug 04, 2025 $51.09
Aug 05, 2025 $47.79
Aug 06, 2025 $48.60
Aug 07, 2025 $47.27
Aug 08, 2025 $45.94
4 days before -8.70%
4 days after -10.08%
On release day -6.46%
Change in period -17.91%
Sep 30, 2025 Beat
Release date Nov 05, 2025
Price on release $164.64
EPS estimate -$3.45
EPS actual -$3.36
EPS surprise 2.61%
Date Price
Oct 30, 2025 $201.00
Oct 31, 2025 $198.76
Nov 03, 2025 $181.99
Nov 04, 2025 $171.75
Nov 05, 2025 $164.64
Nov 06, 2025 $172.35
Nov 07, 2025 $168.22
Nov 10, 2025 $167.89
Nov 11, 2025 $183.56
4 days before -18.09%
4 days after 11.49%
On release day 4.68%
Change in period -8.68%
Dec 31, 2025 Missed
Release date Feb 19, 2026
Price on release $331.61
EPS estimate -$3.13
EPS actual -$3.50
EPS surprise -11.97%
Date Price
Feb 12, 2026 $332.92
Feb 13, 2026 $317.25
Feb 17, 2026 $328.04
Feb 18, 2026 $328.93
Feb 19, 2026 $331.61
Feb 20, 2026 $335.28
Feb 23, 2026 $342.46
Feb 24, 2026 $342.71
Feb 25, 2026 $347.55
4 days before -0.393%
4 days after 4.81%
On release day 1.11%
Change in period 4.39%
Mar 31, 2026 Beat
Release date May 07, 2026
Price on release $333.28
EPS estimate -$3.58
EPS actual -$3.20
EPS surprise 10.61%
Date Price
May 01, 2026 $324.20
May 04, 2026 $337.61
May 05, 2026 $333.30
May 06, 2026 $338.07
May 07, 2026 $333.28
May 08, 2026 $330.02
May 11, 2026 $331.81
May 12, 2026 $343.20
May 13, 2026 $346.84
4 days before 2.80%
4 days after 4.07%
On release day -0.98%
Change in period 6.98%

Praxis Precision Medicines Earnings Call Transcript Summary of Q1 2026

Praxis reported strong operational momentum across its CNS portfolio and continued commercial preparations. Key clinical and regulatory highlights: NDAs for ulixacaltamide (Ulixa) and relutrigine have been accepted by FDA with PDUFA dates set (Ulixa Jan 29, 2027; relutrigine Sept 27, 2026). EMBOLD (broad DEE) enrollment is complete with top-line results expected in Q4 2026; POWER1 (vormatrigine) Phase III readout expected later this quarter; EMBRAVE Part A showed a compelling 77% placebo-adjusted seizure reduction for elsunersen in SCN2A early-onset DEE. The company emphasizes potential large commercial opportunities (management cites >$20B portfolio peak sales potential and >$10B peak for Ulixa) and is actively hiring/building commercial infrastructure, distribution, and patient support. Financials: Q1 operating expenses ~$106M (R&D $78M; SG&A $28M); cash used in operations $86M in Q1; cash and marketable securities $1.4B as of 3/31/2026 (up from $926M at year-end) following a Jan 2026 follow-on offering. Management states cash runway into 2028. Operational notes: dual drug-substance manufacturers for Ulixa, focused launch planning, payer engagement, and continued R&D across ASO and sodium-channel programs. Risks remain from typical clinical, regulatory, and commercial execution uncertainties.

Praxis Precision Medicines Earnings History

Earnings Calendar

FAQ

When is the earnings report for PRAX?
Praxis Precision Medicines, Inc. (PRAX) has scheduled its earnings report for Aug 03, 2026 before the markets open.

What is the PRAX price-to-earnings (P/E) ratio?
PRAX P/E ratio as of Jun 22, 2026 (TTM) is -24.97.

What is the PRAX EPS forecast?
The forecasted EPS (Earnings Per Share) for Praxis Precision Medicines, Inc. (PRAX) for the first fiscal quarter 2026 is -$3.67.

What are Praxis Precision Medicines, Inc.'s retained earnings?
On its balance sheet, Praxis Precision Medicines, Inc. reported retained earnings of $0 for the latest quarter ending Mar 31, 2026.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
GOLDEN STAR
Ticker Change Signal Date
IDYA
$28.98
18.12% Jun 12
DHI
$146.71
6.29% Jun 10
PHM
$118.49
6.02% Jun 10
EAT
$140.46
17.09% Jun 05
E
ETD
$20.67
3.19% Jun 05

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE